7Baggers
Quarterly
Annual
    Unit: USD2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 
      
    		               
      cash flows from operating activities:
    		               
      net income
    		-31,033,000 -50,035,000 -50,133,000 -49,805,000 -48,736,000 -48,352,000 -45,758,000 -53,983,000 -51,975,000 -41,085,000 -45,190,000 -40,946,000 -30,166,000 -31,337,000 -22,749,000 
      adjustments to reconcile net income to net cash from operating activities:
    		               
      depreciation
    		1,716,000 1,700,000 1,754,000 1,667,000 1,632,000 1,517,000 1,474,000 1,337,000 1,127,000 925,000 717,000 648,000 514,000 472,000 412,000 
      non-cash lease expense
    		1,865,000 1,839,000 1,815,000 1,791,000 1,768,000 1,746,000 1,725,000 1,689,000 1,632,000 1,628,000 1,280,000 500,000 499,000 497,000  
      net accretion of discount on marketable securities
    		-1,893,000 -2,155,000 -2,745,000             
      stock-based compensation
    		11,174,000 10,449,000 10,818,000 11,647,000 10,341,000 9,254,000 8,825,000 9,013,000 8,024,000 6,704,000 5,920,000 5,650,000 4,203,000 2,758,000 2,293,000 
      change in fair value of success payments liabilities
    		-223,000 205,000 6,000 -1,671,000 -78,000 713,000 -802,000 662,000 -738,000 -2,177,000 3,306,000 -938,000 -1,677,000 -1,139,000 -700,000 
      changes in operating assets and liabilities:
    		               
      collaboration receivable
    		1,856,000 -626,000 410,000 2,686,000 168,000 -2,775,000    -83,000      
      prepaid expenses and other assets
    		2,117,000  -1,819,000 -4,274,000 -672,000  368,000 -2,006,000 -949,000  -6,474,000 -4,043,000 1,149,000  -5,508,000 
      accounts payable
    		729,000 491,000 -2,568,000 3,553,000 -3,306,000 4,499,000 -2,060,000 -14,000 1,485,000 1,195,000 -5,394,000 4,088,000 -5,105,000 3,485,000 2,061,000 
      accrued expenses and other liabilities
    		-7,515,000 2,460,000 2,257,000 3,559,000 -3,649,000 -3,227,000 3,545,000 1,734,000 -2,283,000 2,380,000 -515,000 8,307,000 -3,131,000 5,113,000 2,448,000 
      operating lease liabilities
    		-1,348,000 -1,272,000 -1,221,000 -1,198,000 -1,234,000 -1,900,000 -1,058,000 -2,698,000 -1,564,000 -170,000 -1,793,000 -525,000 -523,000 -521,000  
      deferred revenue
    		-5,290,000 -2,581,000 1,819,000 1,425,000 4,651,000 2,000    0      
      net cash from operating activities
    		-27,845,000 -40,845,000 -39,607,000 -34,158,000 -43,082,000 -40,680,000 -11,811,000 -47,962,000 -49,096,000 -32,892,000 -29,175,000 -26,758,000 -33,507,000 -28,043,000 -21,355,000 
      capex
    		-1,224,000 -1,387,000 -936,000 -980,000 -433,000 -2,185,000 -1,061,000 -2,662,000 -3,375,000 -4,968,000 -2,637,000 -2,719,000 -2,908,000 -981,000 -1,002,000 
      free cash flows
    		-29,069,000 -42,232,000 -40,543,000 -35,138,000 -43,515,000 -42,865,000 -12,872,000 -50,624,000 -52,471,000 -37,860,000 -31,812,000 -29,477,000 -36,415,000 -29,024,000 -22,357,000 
      cash flows from investing activities:
    		               
      purchases of property and equipment
    		-1,224,000 -1,387,000 -936,000 -980,000 -433,000 -2,185,000 -1,061,000 -2,662,000 -3,375,000 -4,968,000 -2,637,000 -2,719,000 -2,908,000 -981,000 -1,002,000 
      purchases of marketable securities
    		-144,817,000 -73,067,000 -74,830,000 -111,908,000 -164,190,000 -122,323,000 -147,940,000 -113,122,000 -133,755,000 -257,323,000 -147,829,000   -137,004,000 -223,314,000 
      maturities of marketable securities
    		97,873,000 104,000,000 132,578,000 143,038,000 122,991,000 115,615,000 137,167,000 148,809,000 152,522,000 93,978,000 94,950,000 84,750,000 63,000,000 81,000,000 12,000,000 
      net cash from investing activities
    		-48,168,000 29,546,000 56,812,000 30,150,000 -41,632,000 -8,893,000 -11,834,000 33,025,000 15,392,000 -168,313,000 -55,516,000 7,782,000 60,092,000 -56,985,000 -212,316,000 
      cash flows from financing activities:
    		               
      proceeds from issuance of common stock, net of issuance costs
    		 24,301,000 0 -51,000 22,484,000   -65,000 1,987,000       
      proceeds from exercise of stock options
    		7,000 119,000 14,000 826,000 301,000 323,000 213,000 548,000 116,000 442,000 1,108,000 120,000 505,000 442,000 0 
      payment of equity offering costs
    		    -51,000 -393,000    -178,000      
      net cash from financing activities
    		7,000 25,150,000 14,000 1,298,000 22,734,000 177,383,000 31,923,000 1,233,000 2,038,000 39,598,000 288,408,000 445,000 505,000 1,224,000 -867,000 
      decrease in cash, cash equivalents and restricted cash
    		-76,006,000  17,219,000 -2,710,000 -61,980,000           
      cash, cash equivalents and restricted cash—beginning of period
    		177,334,000 0 0 0 210,954,000 0 0 0 120,236,000 0 0 0 69,567,000 0 0 
      cash, cash equivalents and restricted cash—end of period
    		101,328,000 13,851,000 17,219,000 -2,710,000 148,974,000 127,810,000 8,278,000 -13,704,000 88,570,000 -161,607,000 203,717,000 -18,531,000 96,657,000 -83,804,000 -234,538,000 
      supplemental disclosure of noncash investing and financing activities:
    		               
      property and equipment additions included in accounts payable and accrued expenses
    		396,000 -667,000 246,000 -34,000 545,000 1,039,000 -37,000 -1,125,000 1,657,000 -319,000 856,000 -848,000 2,017,000 142,000 -433,000 
      prepaid expenses and other current assets
    		               
      cash flows from financing activities
    		               
      proceeds from the issuance of common stock in connection with collaboration agreements
    		     0          
      issuance of common stock under employee stock purchase plan
    		 796,000 0    0         
      increase in cash, cash equivalents and restricted cash
    		     127,810,000 8,278,000 -13,704,000 -31,666,000 -161,607,000 203,717,000 -18,531,000 27,090,000 -83,804,000 -234,538,000 
      financing costs included in accounts payable and accrued expenses
    		               
      right-of-use assets obtained in exchange for new operating lease liabilities
    		         2,173,000    0  
      net amortization of premium (accretion of discount) on marketable securities
    		    -3,967,000 -3,338,000 -3,493,000 -3,696,000 -3,855,000       
      change in fair value of antidilution rights
    		             0 0 
      success payment liability
    		               
      proceeds from issuance of preferred stock
    		             0 0 
      proceeds from purchase of shares through employee stock purchase plan
    		               
      conversion of convertible preferred stock to common stock upon closing of initial public offering
    		             0 0 
      settlement of derivative liability by issuing common stock
    		               
      proceeds from issuance of common stock, net of commissions
    		               
      offering costs included in accounts payable and accrued liabilities
    		               
      payment of financing costs
    		        -65,000       
      change in fair value of preferred stock tranche liabilities
    		               
      deferred rent liability
    		               
      proceeds from the issuance of common stock in connection with the vertex agreement
    		         0      
      settlement of tranche right liability
    		               
      amortization of premium on marketable securities
    		          -117,000 501,000 730,000 740,000 412,000 
      proceeds from initial public offering, net of underwriting discount
    		             0 0 
      proceeds from issuance of common shares, net of commissions
    		               
      issuance of shares through employee stock purchase plan
    		          0     
      settlement of antidilution rights liability by issuing common stock
    		              0 
      proceeds from issuance of series b convertible preferred stock
    		               
      payment of initial public offering costs
    		             2,000 -867,000 
      initial public offering costs included in accounts payable and accrued liabilities
    		               
      non-cash research and development license expense
    		               
      shareholder loan given
    		               
      payments received on shareholder loan
    		               
      issuance of preferred stock tranche liability
    		               
      cash and cash equivalents
    		               
      restricted cash
    		               
      total cash, cash equivalents and restricted cash
    		               
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.